PSME2

Across TCGA pan-cancer cohorts, PSME2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PSME2 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PSME2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PSME2 expression acts as an unfavorable survival marker.

BLCA, KICH, and SKCM are the cancer types where PSME2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.052	0.710	<.001	48	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SKCM	DFS	Median	III,IV	0.245	0.602	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PSME2–BLCA (OS)

Open the BLCA breakdown →